Scholar Rock Holding Stock Price, News & Analysis

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company developing apitegromab for spinal muscular atrophy (SMA) and other neuromuscular diseases, will host a conference call to discuss Q2 2025 financial results on August 6, 2025, at 8:00am ET.

Investors can access the call by registering online or dialing 800-715-9871 (domestic) or 646-307-1963 (international) with conference ID 3205013. A webcast replay will be available for approximately 90 days on the company's investor relations website.

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company developing apitegromab for spinal muscular atrophy (SMA), has granted inducement equity awards to 6 new employees. The awards include 128,057 stock options at an exercise price of $38.59 and 96,043 restricted stock units.

The awards are part of the Company's 2022 Inducement Equity Plan, designed for new hires. The stock options will vest 25% after one year, with remaining 75% vesting quarterly over three years. Restricted stock units will vest in four equal annual installments, subject to continued employment.

Scholar Rock (SRRK) will present comprehensive data from its successful Phase 3 SAPPHIRE trial of apitegromab at the 2025 Cure SMA Meeting. The trial demonstrated statistically significant and clinically meaningful improvements in motor function for SMA patients, measured by HFMSE. The FDA has accepted apitegromab's BLA with priority review, setting a PDUFA date of September 22, 2025. Additionally, the EMA has validated the Marketing Authorisation Application for apitegromab. Dr. Basil T. Darras will present detailed efficacy and safety data for Type 2 and Type 3 SMA patients on June 27, while Dr. Jena M. Krueger will present a systematic review of long-term SMN-targeted therapy effectiveness on June 25.

Scholar Rock (SRRK) announced positive Phase 2 EMBRAZE trial results for apitegromab combined with tirzepatide for weight loss. The study showed that apitegromab preserved 54.9% more lean mass (+4.2 lbs) compared to tirzepatide alone (p=0.001). Patients receiving the combination therapy lost 12.3% body weight with better quality weight loss (85% fat mass/15% lean mass) versus tirzepatide alone (70% fat mass/30% lean mass). The combination resulted in 18.8 lbs fat mass loss compared to 17.7 lbs with tirzepatide alone. The drug demonstrated a favorable safety profile with no serious adverse events related to apitegromab treatment. While promising for the platform, the company remains focused on apitegromab's potential approval for spinal muscular atrophy (SMA) and plans to file an IND for SRK-439 in H2 2025.

Scholar Rock (SRRK) announced equity inducement grants to 11 new employees, including stock options for 176,963 shares and restricted stock units for 132,737 shares under its 2022 Inducement Equity Plan. The stock options have an exercise price of $34.07, equal to the closing price on June 9, 2025. The options vest 25% after one year and the remaining 75% quarterly over three years, while restricted stock units vest in four equal annual installments. These grants are specifically designed for new hires as employment incentives under Nasdaq Rule 5635(c)(4). Scholar Rock is a late-stage biopharmaceutical company developing apitegromab for spinal muscular atrophy and other neuromuscular diseases.

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company specializing in apitegromab development for spinal muscular atrophy (SMA) and other neuromuscular diseases, announced its participation in the 46th Annual Goldman Sachs Global Healthcare Conference. CEO David L. Hallal and management team members will engage in a fireside chat on June 11, 2025, at 9:20 a.m. ET in Miami, Florida. The presentation will be accessible via live webcast through the company's Investors & Media section, with replay availability for approximately 90 days.

Scholar Rock (SRRK) has appointed Rebecca McLeod as Chief Brand Officer and U.S. General Manager to lead the anticipated U.S. commercial launch of apitegromab for spinal muscular atrophy (SMA) patients. McLeod, a 25-year industry veteran, previously served as argenx U.S. General Manager where she successfully led the launch of VYVGART for gMG and CIDP. In her new role, she will be responsible for establishing global brand strategy and market positioning for apitegromab across Europe, Asia-Pacific, and Latin America. McLeod's extensive experience includes leadership positions at Alexion Pharmaceuticals and Takeda Pharmaceuticals, with her most recent achievement being one of the most successful biopharmaceutical franchise launches with VYVGART at argenx.

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company specializing in developing apitegromab for spinal muscular atrophy (SMA) and other neuromuscular diseases, announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO David L. Hallal and the management team will engage in a fireside chat on June 4 at 3:45 p.m. ET in New York City. The presentation will be accessible via live webcast through Scholar Rock's Investors & Media website section, with replay availability for approximately 90 days.

Scholar Rock (SRRK), a late-stage biopharmaceutical company focused on developing apitegromab for spinal muscular atrophy (SMA), has granted inducement equity awards to 14 new employees. The awards include 60,400 shares in stock options with an exercise price of $32.46 and 45,300 shares in restricted stock units.

The stock options will vest 25% after one year from each employee's start date, with the remaining 75% vesting in 12 quarterly installments. The restricted stock units will vest in four equal annual installments. These awards were granted under the Company's 2022 Inducement Equity Plan, specifically designed for new hires as per Nasdaq Listing Rule 5635(c)(4).